A biotech with a yen for pricey rare dis­ease drugs — and bar­gain base­ment shop­ping — adopts an­oth­er or­phan in lat­est M&A pact

Af­ter mak­ing it through a long, painful haul to get past a CRL and on to an FDA ap­proval last sum­mer, lit­tle Chi­as­ma has found a buy­er.

Am­ryt $AMYT, a com­pa­ny known for its ap­petite for ac­quir­ing ex­pen­sive drugs for rare dis­eases at bar­gain prices, snagged Chi­as­ma and its acromegaly drug My­capssa (oc­treotide) cap­sules in an all-stock deal — with an ex­change of 0.396 shares of Am­ryt for every share of Chi­as­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER